Compare KRNY & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | AGMB |
|---|---|---|
| Founded | 1884 | 2017 |
| Country | United States | Belgium |
| Employees | 557 | 62 |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.9M | 562.4M |
| IPO Year | 2014 | N/A |
| Metric | KRNY | AGMB |
|---|---|---|
| Price | $8.01 | $10.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.25 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 259.5K | 80.5K |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 130.22 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | $17.86 |
| P/E Ratio | $17.36 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.76 | $9.00 |
| 52 Week High | $8.50 | $17.45 |
| Indicator | KRNY | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 41.37 |
| Support Level | $7.77 | $9.62 |
| Resistance Level | $8.27 | $12.29 |
| Average True Range (ATR) | 0.16 | 0.99 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 52.87 | 10.39 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.